vimarsana.com

Page 46 - ஆக்ஸ்ஃபர்ட் பல்கலைக்கழகம் நுஃபையீல்ட் துறை ஆஃப் மருந்து News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Asthma drug budesonide shortens recovery time in non-hospitalised patients with COVID-19

Share Early treatment with inhaled budesonide shortens recovery time by a median of three days in patients with COVID-19 who are at higher risk of more severe illness and are treated in the community, finds Oxford University’s Platform Randomised Trial of Interventions against COVID-19 in Older People (PRINCIPLE) trial. PRINCIPLE is the world’s largest Phase 3 platform randomised controlled trial to find clear evidence of an effective COVID-19 treatment for use in the community that can significantly shorten recovery time. As one of the UK Government’s national priority platform trials, findings from PRINCIPLE have potential to change how COVID-19 is treated in its early stages in non-hospital, community settings in the UK and internationally.

First drug for Covid in the community given green light

First drug for Covid in the community given green light  Oxford University researchers found that inhaled budesonide cuts illness time by three days in the most at-risk patients Researchers noticed that people with asthma were under-represented in hospitalised Covid patients Credit: Brian Lawless /PA The first treatment for coronavirus in the community has been approved by the Department of Health after Oxford University found that a cheap asthma drug cuts illness times by three days.  There is currently no specific treatment for coronavirus, with patients usually being advised to take paracetamol to reduce their fever, or cough medicine. However, Oxford University found that in the most at-risk patients, inhaled budesonide clears up the infection far more quickly and may even prevent hospitalisation and long Covid.

© 2025 Vimarsana

vimarsana © 2020. All Rights Reserved.